论文部分内容阅读
目的评价厄贝沙坦/氢氯噻嗪复方片剂治疗原发性高血压的有效性和安全性。方法80例原发性高血压患者服用厄贝沙坦/氢氯噻嗪复方片剂,疗程4周。结果80例中显效47例(58.75%),有效26例(32.5%),无效7例(8.75%),总有效率91.25%,治疗4周后与治疗前比较,坐位血压明显下降,治疗前为(170±15)/(98±8)mm Hg,治疗后为(137±10)/(76±7)mm Hg,但心率无明显变化(P>0.05)。检测24 h动态血压,计算降压谷峰比值率>65%。结论厄贝沙坦/氢氯噻嗪复方片剂治疗原发性高血压安全有效。
Objective To evaluate the efficacy and safety of irbesartan / hydrochlorothiazide combination tablet in the treatment of essential hypertension. Methods 80 patients with essential hypertension taking irbesartan / hydrochlorothiazide compound tablets for 4 weeks. Results Among the 80 cases, 47 (58.75%) were effective, 26 (32.5%) were effective, 7 (8.75%) were ineffective and the total effective rate was 91.25%. After 4 weeks of treatment, Was (170 ± 15) / (98 ± 8) mm Hg after treatment and was (137 ± 10) / (76 ± 7) mm Hg after treatment, but there was no significant change in heart rate (P> 0.05). Ambulatory blood pressure was measured 24 h, calculated trough peak ratio> 65%. Conclusion Irbesartan / hydrochlorothiazide combination tablet is safe and effective in treating essential hypertension.